Flash e-reader

 Go to e-reader chapter








Table 9.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Liver Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 5,001 5,195 5,332 5,673 6,171 6,444 6,651 6,494 6,319 6,320
With Immunosuppression Info 4,854 5,035 5,199 5,520 5,974 6,166 6,410 6,278 6,147 6,192
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 0.7% 0.4% 0.5% 0.5% 0.4% 0.2% 0.3% 1.2% 1.1% 0.7%
OKT3 0.8% 0.7% 0.3% 0.3% 0.2% 0.8% 2.7% 2.9% 2.5% 2.4%
Thymoglobulin 1.2% 2.4% 4.2% 6.5% 7.4% 7.2% 9.0% 9.5% 10.3% 9.4%
Zenapax 6.6% 5.8% 4.6% 5.6% 4.8% 4.0% 5.8% 8.1% 7.8% 6.5%
Simulect 6.6% 6.2% 7.8% 7.2% 6.4% 7.1% 6.5% 5.6% 6.8% 8.7%
Campath 0.0% 0.0% 0.0% 0.7% 1.6% 1.6% 1.4% 1.4% 1.0% 0.7%
No Induction Drugs Recorded 84.5% 84.6% 82.7% 79.5% 79.4% 79.9% 77.2% 74.4% 73.4% 74.1%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.